Related Experiment Videos
Local tumour resection in interferon treated osteosarcoma patients
U Nilsonne1, L A Broström, T Aparisi
1Department of Orthopaedics, Karolinska Hospital, Stockholm, Sweden.
Annales Chirurgiae Et Gynaecologiae
|January 1, 1995
Summary
Adjuvant human leucocyte interferon combined with limb-sparing surgery for osteosarcoma showed promising long-term results, with half of patients remaining recurrence-free over 15 years.
Area of Science:
- Orthopedic Oncology
- Immunotherapy
- Surgical Oncology
Background:
- Osteosarcoma is a primary bone cancer often requiring aggressive surgical treatment.
- Limb preservation strategies are increasingly important in oncologic surgery.
- Human leucocyte interferon (hLI) has been explored as an adjuvant therapy.
Observation:
- Fifteen patients with primary classical osteosarcoma underwent en bloc resection and adjuvant hLI therapy.
- Long-term follow-up exceeding fifteen years was conducted for all patients.
- Treatment allowed for limb preservation as an alternative to ablative surgery.
Findings:
- 50% of patients demonstrated no evidence of tumor recurrence after more than 15 years.
- Eight patients succumbed to generalized osteosarcoma disease.
- Two patients developed distant lung metastases, diagnosed 5 and 8 years post-surgery.
Implications:
- Limb-sparing surgery combined with adjuvant hLI offers a viable alternative for select osteosarcoma cases.
- This multimodal approach may improve long-term outcomes in osteosarcoma patients.
- Specialized centers with expert surgical teams are crucial for successful implementation of this treatment strategy.